MX2018006969A - Método de preparación de la forma ii hidrato del cocristal de valasartán y ahu-377 trisódico. - Google Patents

Método de preparación de la forma ii hidrato del cocristal de valasartán y ahu-377 trisódico.

Info

Publication number
MX2018006969A
MX2018006969A MX2018006969A MX2018006969A MX2018006969A MX 2018006969 A MX2018006969 A MX 2018006969A MX 2018006969 A MX2018006969 A MX 2018006969A MX 2018006969 A MX2018006969 A MX 2018006969A MX 2018006969 A MX2018006969 A MX 2018006969A
Authority
MX
Mexico
Prior art keywords
crystal form
solvent
diovan
ahu
trisodium salt
Prior art date
Application number
MX2018006969A
Other languages
English (en)
Inventor
Zhang Yanfeng
Chen Minhua
Zhang Liang
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of MX2018006969A publication Critical patent/MX2018006969A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación se refiere a un método de preparación de una forma II hidrato del cocristal de Valsartán y AUH-377 trisódico; el método de preparación comprende: en primer lugar, preparar una solución transparente de AHU-377 trisódico y Valsartán, el disolvente de la solución transparente comprende un antidisolvente y un buen solvente del producto objetivo que es la Forma II, y el punto de ebullición del buen disolvente es inferior a aquel del antidisolvente; en segundo lugar, evaporar la solución bajo vacío para eliminar el buen disolvente y agua del sistema; y finalmente, opcionalmente agregar cristales semilla de la Forma II o no y reponer una mezcla de agua y un disolvente portador para agitar para cristalización; el método de la presente divulgación puede preparar la Forma II con éxito, y el proceso es consistente y controlable; el producto que es la Forma II obtenida tiene alta pureza química, pureza cristalina buena fluidez; y el proceso se puede llevar a cabo a una mayor escala y cumplir con los requisitos de producción a gran escala.
MX2018006969A 2015-12-08 2016-11-10 Método de preparación de la forma ii hidrato del cocristal de valasartán y ahu-377 trisódico. MX2018006969A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510902127.7A CN106854187B (zh) 2015-12-08 2015-12-08 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
PCT/CN2016/105335 WO2017097085A1 (zh) 2015-12-08 2016-11-10 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法

Publications (1)

Publication Number Publication Date
MX2018006969A true MX2018006969A (es) 2018-11-29

Family

ID=59013701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006969A MX2018006969A (es) 2015-12-08 2016-11-10 Método de preparación de la forma ii hidrato del cocristal de valasartán y ahu-377 trisódico.

Country Status (12)

Country Link
US (1) US10442775B2 (es)
EP (1) EP3385256B1 (es)
JP (1) JP6628884B2 (es)
KR (1) KR102070392B1 (es)
CN (1) CN106854187B (es)
AU (1) AU2016368863B2 (es)
CA (1) CA3007864C (es)
ES (1) ES2862204T3 (es)
IL (1) IL259871A (es)
MX (1) MX2018006969A (es)
PL (1) PL3385256T3 (es)
WO (1) WO2017097085A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970192C (en) * 2014-12-08 2020-08-04 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
EP3522886A4 (en) 2016-10-10 2020-02-19 Laurus Labs Limited STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR102543230B1 (ko) 2019-05-24 2023-06-14 주식회사 파마코스텍 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
CN116646606B (zh) * 2023-07-13 2024-05-03 常州千沐新能源有限公司 一种采用磺酸酯基深共晶溶剂的电解液、制备方法以及锂离子电池

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CA2970192C (en) * 2014-12-08 2020-08-04 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
CN105037289B (zh) * 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型

Also Published As

Publication number Publication date
EP3385256B1 (en) 2021-02-24
CA3007864A1 (en) 2017-06-15
JP6628884B2 (ja) 2020-01-15
ES2862204T3 (es) 2021-10-07
CA3007864C (en) 2021-03-23
EP3385256A4 (en) 2018-12-19
WO2017097085A1 (zh) 2017-06-15
US10442775B2 (en) 2019-10-15
KR20180090346A (ko) 2018-08-10
IL259871A (en) 2018-07-31
PL3385256T3 (pl) 2021-09-27
US20180354916A1 (en) 2018-12-13
EP3385256A1 (en) 2018-10-10
JP2019503999A (ja) 2019-02-14
AU2016368863B2 (en) 2019-11-14
CN106854187B (zh) 2020-04-14
KR102070392B1 (ko) 2020-01-28
AU2016368863A1 (en) 2018-07-26
CN106854187A (zh) 2017-06-16

Similar Documents

Publication Publication Date Title
MX2018006969A (es) Método de preparación de la forma ii hidrato del cocristal de valasartán y ahu-377 trisódico.
WO2016161989A3 (zh) 一种硫酸氢氯吡格雷i晶型球形结晶的制备方法
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
PH12019500943A1 (en) Method for producing allulose crystals
RS54078B1 (en) PRODUCTION OF HIGH PURITY CALCIUM-CARBONATE
PH12014501457B1 (en) Method for producing cobalt sulfate
MX2017011990A (es) Metodo de preparacion de la forma a cristalina de pci-32765.
PH12017501745A1 (en) Cobalt powder production method
WO2014178075A3 (en) Ionic liquid compound
HRP20171707T1 (hr) Postupak proizvodnje rivaroksabana
MY169158A (en) Method for manufacturing succinic acid estres
PH12016502359A1 (en) Lobaplatin crystals, preparation methods and pharmaceutical applications
PH12020500586A1 (en) Process for preapring large size isoxazoline particles
PH12019500435A1 (en) Method for producing scandium compound, and scandium compound
MX2019001855A (es) Procesos para remover compuesto a base de nitrogeno de una corriente de gas o liquido para producir producto a base de nitrogeno.
MY192148A (en) Steviol glycoside composition
MX2017011790A (es) Metodo para fabricar acido furan-2,5-dicarboxilico (fdca) a partir de una sal solida.
WO2012115402A3 (en) Crystalline form of docetaxel and process for preparation thereof
HRP20200755T1 (hr) Postupak kristalizacije za dobivanje kristala kanagliflozin hemihidrata
PH12018501046B1 (en) Crystal of monovalent cation salt of 3-hydroxyisovaleric acid and process for producing the crystals
WO2016105106A3 (ko) 무수당 알코올의 연속적인 생산방법
MX2017007376A (es) Proceso para producir anhidrido 4-azidosulfonilftalico.
CN104447345B (zh) 一种噁草酮醚化废盐渣再利用的处理方法
CN104672190B (zh) 一种赤霉素母液再结晶的方法
SG11201808954RA (en) Method for purifying methacrylic acid and method for producing methacrylic acid